Skip to content

Nuvation Bio NUVB Deferred Revenue

Deferred Revenue at other companies

Immunome logo
ImmunomeIMNM
$0-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$34M-52.8%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$490K
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$2.8M
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$1.27M-42.4%
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's deferred revenue?
Nuvation Bio (NUVB) reported deferred revenue of $8.65M in Q1 2026.
How has Nuvation Bio's deferred revenue changed year-over-year?
Nuvation Bio's deferred revenue decreased by 19.7% year-over-year, from $10.77M to $8.65M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.